Hydromorphone With Electroacupuncture and Ear Acupoint Pressing for Refractory Cancer Pain

This trial aims to address refractory cancer pain (RCP). It will explore the synergistic efficacy and safety of hydromorphone hydrochloride sustained-release tablets (HHST) combined with electroacupuncture (EA) and ear acupoint pressing beans (EAPB) for RCP. Key outcomes will include dynamic changes in Numerical Rating Scale (NRS) scores, proportions of patients with effective analgesia (≥30% NRS reduction from baseline) and marked remission (≥50% NRS reduction from baseline), daily HHST dosage, breakthrough pain (BP) frequency, and drug-related adverse events (AEs) graded by CTCAE 6.0.

NCT Number	NCT07489625
Lead Sponsor	Qinghai Red Cross Hospital
Conditions	Refractory Cancer Pain, Cancer Pain
Enrollment	30 participants
Start Date	2026-08-05
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-14